demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 outpatients
Immunostimulants drugs
convalescent plasma treatment CONV-ERT CoV-Early ... C3PO
Early convalescent plasma. CoV-Early ...
interferon
inhaled interferon
SNG001 inhaled interferon beta ACTIV-2 SNG001
peginterferon Feld TOGETHER interferon lambda
neutralizing antibody
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-2 ...
bamlanivimab monotherapy BLAZE-1 phase 2 ... OPTIMISE-C19 ...
bamlanivimab/etesevimab BLAZE-4 BLAZE-1 phase 2 ... BLAZE-1 phase 3 ... OPTIMISE-C19 ...
Bebtelovimab (LY-CoV1404) BLAZE 4 LY-CoV1404
casirivimab/imdevimab (Ronapreve) Cov-2067 Weinreich ... Mazzotta Cov-2069 ...
cilgavimab and tixagevimab (Evusheld) TACKLE
regdanvimab (Regkirona- CT-P59-Celltrion) CT-P59 3.2 part 2 CT-P59 3.2 part 1
sotrovimab (Xevudy; VIR-7831) COMET-ICE

17 studies excluded by filtering options 1

4861 Cai -FAVIPIRAVIR, 2020 1310not a RCTrisk of bias not avaialble
5183 Qiong Zhou, 2020 0190selection pending
5406 Duan, 2020 1134not a RCThigh risk of bias
5446 Sean, 2020 1134not a RCThigh risk of bias
5450 Pereda, 0 0100selection pending
5534 Wang (early IFN), 2020 0134selection pending
5549 Hegerova, 2020 1134not a RCThigh risk of bias
5550 Abolghasemi, 2020 1134not a RCThigh risk of bias
5565 Pereda, 2020 0130selection pending
5569 Dai W, 2020 2134excludednot a RCThigh risk of bias
5572 Hao, 2020 0200selection pending
5662 Salazar, 2020 1134not a RCThigh risk of bias
5761 Joyner, 2020 1313not a RCThigh risk of bias
6140 Wang, 2020 0130selection pending
6159 Gemici, 2020 0130selection pending
6708 Webb, 2021 0130selection pending
6940 Bihariesingh-Sanchit (SuriCovid), 2021 1310not a RCTrisk of bias not avaialble